About: Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications
Creator	Wong, Karen Barton, Michael Batumalai, Vikneswary Delaney, Geoff Descallar, Joseph Gabriel, Gabriel Shafiq, Jesmin
source	Elsevier; Medline; PMC
abstract	BACKGROUND AND PURPOSE: Substantial variation in the adoption of hypofractionation for breast radiation therapy has been observed, despite the availability of consensus guidelines. This study aimed to investigate the variation in radiation therapy fractionation in breast cancer patients in New South Wales (NSW), Australia, and to estimate survival outcome and cost implications. MATERIALS AND METHODS: This is a population-based cohort of patients who received radiation therapy for breast cancer (2009-2013), as captured in the NSW Central Cancer Registry. A logistic regression model was used to identify factors associated with fractionation type. Survival outcome was estimated using multivariable Cox proportional hazards model. Cost per treatment and potential cost saving associated with evidence-based fractionation was estimated. RESULTS: A total of 10,482 patients were available for analysis, divided into 3 cohorts (breast alone: N = 7000; breast + nodes: N = 1119; all chestwall: N = 2363). In multivariable analysis, increasing age, laterality (right), year of treatment (2013), early stage, lower socioeconomic status, and regional area of residence were independent predictors of hypofractionation for breast alone radiation therapy. For the breast + nodes and chest wall cohorts, common factors that predicted the use of hypofractionation were increasing age. In multivariable survival analysis, there was no difference between the fractionation regimens at 5 years. Estimated radiation therapy cost of this cohort approximated $52.1 million, compared with $38.5 million had these patients been treated with evidence-based fractionation. This demonstrated a potential saving of $13.6 million. CONCLUSION: Hypofractionation appears underused for breast radiation therapy in NSW over time. This study highlights that evidence-based practice will translate to reduced health care treatment costs.
has issue date	2020-07-25(xsd:dateTime)
bibo:doi	10.1016/j.radonc.2020.07.038
bibo:pmid	32721419
has license	no-cc
sha1sum (hex)	679051bcff8a2c3f8ff3d97edbcbb304afbed08a
schema:url	https://doi.org/10.1016/j.radonc.2020.07.038
resource representing a document's title	Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications
has PubMed Central identifier	PMC7382346
has PubMed identifier	32721419
schema:publication	Radiother Oncol
resource representing a document's body	covid:679051bcff8a2c3f8ff3d97edbcbb304afbed08a#body_text
is schema:about of	named entity 'radiotherapy' named entity 'Survival' named entity 'cost' named entity 'breast cancer' named entity 'breast cancer' named entity 'Oncology' named entity 'Variation' named entity 'fractionation' named entity 'Radiotherapy' named entity 'radiotherapy' named entity 'doi' named entity 'radiotherapy' named entity 'advanced breast cancer' named entity 'breast cancer' named entity 'Australia' named entity 'hypofractionation' named entity 'chest wall' named entity 'chest wall' named entity 'RVU' named entity 'SES' named entity 'Kaplan-Meier' named entity 'breast cancer' named entity 'SES' named entity 'Hypofractionation' named entity 'survival analysis' named entity 'health care' named entity 'NSW' named entity 'radiation therapy' named entity 'chest wall' named entity 'hypofractionation' named entity 'radiation oncologist' named entity 'hypofractionation' named entity 'hypofractionation' named entity 'significant difference' named entity 'chest wall' named entity 'Australia' named entity 'quality of life' named entity 'Canada' named entity 'hypofractionation' named entity 'COVID-19' named entity 'chest wall' named entity 'advanced stage' named entity 'hypofractionation' named entity 'Australia' named entity 'NSW' named entity 'SES' named entity 'hypofractionation' named entity 'activity-based costing' named entity 'hypofractionation' named entity 'Data Collection' named entity 'Australia' named entity 'SES' named entity 'hypofractionation' named entity 'breast cancer' named entity 'randomised trial' named entity 'Australia' named entity 'NSW' named entity 'hypofractionation' named entity 'hypofractionation' named entity 'hypofractionation' named entity 'hypofractionation' named entity 'breast cancer' named entity 'hypofractionation' named entity 'TNM staging' named entity 'hypofractionation' named entity 'Cancer Institute' named entity 'NSW' named entity 'hypofractionation' named entity 'Health Record' named entity 'hypofractionation' named entity 'NSW' named entity 'Hypofractionation' named entity 'SES' named entity 'patient satisfaction' named entity 'hypofractionation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software